Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145448 | 0.88 | NPC1 (0.49) | NPC1RAB9ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2145585 | 0.86 | MAPK1 (0.54) | RAB9AL3MBTL1TDP1SMN1; SMN2MAPT | |
| SCHEMBL2146065 | 0.86 | GABRA1 (0.48) | MAPTALDH1A1 | |
| SCHEMBL2145861 | 0.84 | L3MBTL1 (0.52) | NPC1RAB9AL3MBTL1TSHRGAA | |
| SCHEMBL2145473 | 0.82 | GAA (0.51) | NPC1RAB9AL3MBTL1TSHRGAA | |
| SCHEMBL2145110 | 0.81 | TSHR (0.52) | NPC1RAB9ATSHRGAASMN1; SMN2 | |
| SCHEMBL2146055 | 0.81 | RAB9A (0.45) | NPC1RAB9AL3MBTL1TSHRGAA | |
| SCHEMBL2454528 | 0.76 | MEN1 (0.47) | NPC1RAB9AL3MBTL1TSHRGAA | |
| SCHEMBL2145870 | 0.74 | MAPK1 (0.57) | NPC1RAB9AL3MBTL1TSHRGAA | |
| SCHEMBL2145878 | 0.73 | RXFP1 (0.48) | NPC1RAB9AGAASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | claimed |
| US-8329738-B2 | Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PRKAG1, PRKAB1, PRKAG2 | NPC1 1430/4885RAB9A 2518/4885L3MBTL1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.